newswire, breaking biotechnology and pharma news

Friday, February 24, 2012

Biotech Stocks Sector Snapshot and Podcast: VVUS, INFI, SNTS on the Move

New York, NY - February 24, 2012 -, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for notable sector gainers VIVUS, Inc. (NASDAQ: VVUS), Infinity Pharmaceuticals (Nasdaq:INFI) and Santarus, Inc. (NASDAQ:SNTS). sector snapshot podcast for biotech stocks, for trading as of Thursday February 23 rd:

Listen to the Podcast in MP3

VIVUS, Inc. (NASDAQ: VVUS) closed up with massive gains at $18.73, up $8.18(77.54%) with after hours trading moving it to $!8.95, up another 0.22 (1.17%).The day's high on the stock was $21.44 on over 58 Million shares. The stock's monster move was on news that the FDA Advisory Committee had recommended the approval of Qnexa for the treatment of obesity in adults

Infinity Pharmaceuticals (NASDAQ:INFI) closed up at $7.15, up 0.84 or (13.31%). The Company announced on Tuesday that they will be presenting at the Cowen and Company 32nd Annual Health Care Conference on Monday, March 5th

Santarus, Inc. (NASDAQ:SNTS) finished the day at $5.01 up 0.51(11.33%). The Company announced Wednesday that they have entered into a settlement agreement with Lupin to resolve pending patent litigation involving GLUMETZA


VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead investigational product in clinical development, Qnexa, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. VIVUS received a Complete Response Letter, or CRL, to the initial Qnexa NDA on October 28, 2010. We resubmitted the Qnexa NDA in October 2011, with an FDA action date of April 17, 2012. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS has submitted an NDA for avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction, with an FDA action date of April 29, 2012.

Get biotech news and stock alerts

Research more biotech stocks at the Biotech stocks Directory:

About is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.

Follow on Twitter!/Investorideas

Follow on Facebook

Disclaimer/ Disclosure : The is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.

BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info:


Source -

No comments:

Post a Comment